Skip to main content

Table 2 Inhibitory effects of pimprinine, pimprinethine, WS-30581 A and WS-30581 B against other human viruses

From: Antiviral effects against EV71 of pimprinine and its derivatives isolated from Streptomyces sp

Tested compound

 

CVB3

HSV-1

ADV-7

H1N1

 

CC50a

443 ± 35e

443 ± 35

1140 ± 181

899 ± 56

Pimprinine

EC50b

95 ± 16

160 ± 18

150 ± 10

—

 

EC90c

—f

—

266 ± 14

—

 

SId

5

3

8

—

 

CC50

256 ± 49

256 ± 49

750 ± 30

577 ± 73

Pimprinethine

EC50

22 ± 4

45 ± 3

33 ± 6

—

 

EC90

58 ± 9

—

63 ± 5

—

 

SI

12

6

23

—

 

CC50

72 ± 8

72 ± 8

217 ± 4

212 ± 18

WS-30581 A

EC50

14 ± 4

18 ± 2

17 ± 18

38 ± 7

 

EC90

39 ± 4

—

43 ± 3

—

 

SI

5

4

13

6

 

CC50

83 ± 6

83 ± 6

354 ± 14

215 ± 28

WS-30581 B

EC50

12 ± 2

14 ± 4

15 ± 2

24 ± 5

 

EC90

42 ± 6

—

48 ± 6

—

 

SI

7

6

24

9

 

CC50

1311 ± 385

 

1516 ± 243

 

Ribaviring

EC50

90 ± 10

 

116 ± 19

 
 

EC90

103 ± 17

 

132 ± 22

 
 

SI

15

 

13

 
 

CC50

 

>2000

  

Acyclovirh

EC50

 

11 ± 1

  
 

EC90

 

24 ± 5

  
 

SI

 

>181

  
 

CC50

   

>2000

Amantadinei

EC50

   

73 ± 8

 

EC90

   

90 ± 12

 

SI

   

>27

  1. aCC50, compound concentration required to reduce cell viability by 50%.
  2. bEC50, compound concentration required to achieve 50% protection from virus-induced cytopathogenicity.
  3. cEC90, compound concentration required to inhibit 90% virus yield.
  4. dSI (selectivity index), ratio CC50/EC50.
  5. eValues represent the mean ± SD of three independent experiments.
  6. f—, less than 50% or 90% inhibition; g, h, iRibavirin, acyclovir and amantadine, used as positive controls.